Changcheng Zheng

机构：University of Science and Technology of China, Anhui Medical University, Anhui Provincial Hospital, First Affiliated Hospital of Anhui Medical University, Duke Kunshan University, CAE (Canada) · ORCID：0000-0002-1976-6415

发表论文 118 篇 · 总被引 1425 次 · h-index 18

代表论文

• Reduced doses of emicizumab achieve good efficacy: Results from a national‐wide multicentre real‐world study in China (2024 · Haemophilia · 被引 16)
• Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia (2024 · Cell Reports Medicine · 被引 14)
• Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: A multicenter, randomized, double-blind, placebo-controlled, phase III trial (2023 · Journal of Translational Internal Medicine · 被引 13)
• Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials (2025 · Nature Medicine · 被引 9)
• Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes (2023 · ImmunoTargets and Therapy · 被引 9)
• Thrombopoietin receptor agonists regulate myeloid-derived suppressor cell-mediated immunomodulatory effects in ITP (2024 · Annals of Hematology · 被引 6)